Literature DB >> 16972717

Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: opportunities and limitations.

Christopher Jenniso1, Bruce W Turnbull.   

Abstract

This is a discussion of the following two papers in this special issue on adaptive designs: 'Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: General concepts' by Frank Bretz, Heinz Schmidli, Franz König, Amy Racine and Willi Maurer, and 'Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: Applications and practical considerations' by Heinz Schmidli, Frank Bretz, Amy Racine and Willi Maurer.

Entities:  

Mesh：

Year:  2006        PMID： 16972717     DOI： 10.1002/bimj.200610248

Source DB:  PubMed          Journal:  Biom J        ISSN： 0323-3847            Impact factor:   2.207


  9 in total

1.  Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment.

Authors:  M Rosenblum; M J Van der Laan
Journal:  Biometrika       Date:  2011-12       Impact factor: 2.445

2.  A Hybrid Geometric Phase II/III Clinical Trial Design based on Treatment Failure Time and Toxicity.

Authors:  Peter F Thall; Hoang Q Nguyen; Xuemei Wang; Johannes E Wolff
Journal:  J Stat Plan Inference       Date:  2012-04-01       Impact factor: 1.111

3.  Adaptive choice of patient subgroup for comparing two treatments.

Authors:  Tze Leung Lai; Philip W Lavori; Olivia Yueh-Wen Liao
Journal:  Contemp Clin Trials       Date:  2014-09-07       Impact factor: 2.226

Review 4.  Integrated phase II/III clinical trials in oncology: a case study.

Authors:  Meihua Wang; James J Dignam; Qiang E Zhang; John F DeGroot; Minesh P Mehta; Sally Hunsberger
Journal:  Clin Trials       Date:  2012-11-22       Impact factor: 2.486

5.  Optimizing the data combination rule for seamless phase II/III clinical trials.

Authors:  Lisa V Hampson; Christopher Jennison
Journal:  Stat Med       Date:  2014-10-15       Impact factor: 2.373

6.  Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial.

Authors:  Nigel Stallard; Cornelia Ursula Kunz; Susan Todd; Nicholas Parsons; Tim Friede
Journal:  Stat Med       Date:  2015-06-26       Impact factor: 2.373

7.  Commentary: Arguing for Adaptive Clinical Trials in Sepsis.

Authors:  Miriam Kesselmeier; André Scherag
Journal:  Front Immunol       Date:  2018-10-30       Impact factor: 7.561

Review 8.  Experimental designs for small randomised clinical trials: an algorithm for choice.

Authors:  Catherine Cornu; Behrouz Kassai; Roland Fisch; Catherine Chiron; Corinne Alberti; Renzo Guerrini; Anna Rosati; Gerard Pons; Harm Tiddens; Sylvie Chabaud; Daan Caudri; Clément Ballot; Polina Kurbatova; Anne-Charlotte Castellan; Agathe Bajard; Patrice Nony; Leon Aarons; Agathe Bajard; Clément Ballot; Yves Bertrand; Frank Bretz; Daan Caudri; Charlotte Castellan; Sylvie Chabaud; Catherine Cornu; Frank Dufour; Cornelia Dunger-Baldauf; Jean-Marc Dupont; Roland Fisch; Renzo Guerrini; Vincent Jullien; Behrouz Kassaï; Patrice Nony; Kayode Ogungbenro; David Pérol; Gérard Pons; Harm Tiddens; Anna Rosati; Corinne Alberti; Catherine Chiron; Polina Kurbatova; Rima Nabbout
Journal:  Orphanet J Rare Dis       Date:  2013-03-25       Impact factor: 4.123

9.  Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs.

Authors:  Thomas Burnett; Pavel Mozgunov; Philip Pallmann; Sofia S Villar; Graham M Wheeler; Thomas Jaki
Journal:  BMC Med       Date:  2020-11-19       Impact factor: 8.775
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.